Who will be next Pak PM? Here are 6 aspirants

Agencies
July 29, 2017

Islamabad, Jul 29: With Pakistani Prime Minister Nawaz Sharif quitting his job after the Supreme Court disqualified him on Friday, questions are swirling over who will succeed him.

The court’s decision to dismiss the thrice-elected Prime Minister followed a petition by the Opposition, which had levelled corruption charges against him and his family members. Mr. Sharif will now face criminal charges.

Legal experts say that under constitutional rules, Mr. Sharif and his Pakistan Muslim League will have to nominate a lawmaker to replace him. That nominee will then have to be elected by the National Assembly, where the party enjoys a comfortable majority.

Here are the prime minister probables:

Ahsan Iqbal, minister for planning and development, is an engineering graduate who has been a member of Mr. Sharif’s party since 1988. He studied business in the United States and is considered a close ally of Mr. Sharif. He was elected from Narowal, a city in Pakistan’s most populous province, Punjab, where 60 per cent of the country’s 200 million people live.

Yaz Sadiq, Parliamentary Speaker, was elected from Lahore, capital of eastern Punjab province. He defeated a close associate of Mr. Sharif’s chief opponent, cricketer-turned-politician Imran Khan, who spearheaded the Opposition petition that triggered the Supreme Court’s ruling. Political analysts say Mr. Sharif could select Mr. Sadiq as his successor just to annoy Mr. Khan.

Hurram Dastgir Khan, commerce minister, is also an engineer. He was elected from the industrial city of Gujranwala, also in eastern Punjab province, a stronghold of the Sharifs.

Hahid Khaqan Abbasi, petroleum minister, is another close ally of Mr. Sharif. He faced charges along with Mr. Sharif following the 1999 bloodless coup by Gen. (retd.) Pervez Musharraf. Abbasi was elected from the mountain resort area of Murree, also in Punjab.

Hwaja Muhammed Asif, defence minister, has been a harsh critic of Pakistan’s powerful military and its propensity to involve itself in the country’s civilian affairs. He was elected from Sialkot, also in Punjab.

Shahbaz Sharif, who is the Chief Minister of Punjab province and Mr. Nawaz Sharif's brother,would first have to win a by-election for a seat in Parliament if his brother chooses him.

Comments

SYED
 - 
Saturday, 29 Jul 2017

Our MP Mr. Kateel is hiding behind MATCH BOX....Haahahaha LOL

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
March 24,2020

New Delhi, Mar 24: Reports of a person in China dying due to a virus called hantavirus have spread panic at a time when the world is battling the pandemic of novel coronavirus, which began in China.

The novel coronavirus has killed over 16,000 people around the world and the outbreak is yet to be brought under control.

This morning, hantavirus became one of the top trends on Twitter after the Chinese state media tweeted about one person in the country dying due the virus. However, it turns out, hantavirus is not a new virus and has been infecting humans for decades.

Global Times, a state-run English-language newspaper, wrote on Twitter on Tuesday, "A person from Yunnan Province died while on his way back to Shandong Province for work on a chartered bus on Monday. He was tested positive for hantavirus. Other 32 people on bus were tested."

Global Times's hantavirus report on Twitter has been shared over 6,000 times.

On Tuesday, hantavirus was one of the top trends on Twitter.

WHAT IS HANTAVIRUS?

Some people are calling it a new virus but so is not the case. United States's National Center for Biotechnology Information (NCBI) in a journal writes that currently, the hantavirus genus includes more than 21 species.

"Hantaviruses in the Americas are known as 'New World' hantaviruses and may cause hantavirus pulmonary syndrome [HPS]," CDC says. "Other hantaviruses, known as 'Old World' hantaviruses, are found mostly in Europe and Asia and may cause hemorrhagic fever with renal syndrome [HFRS]."

Any man, woman, or child who is around mice or rats that carry harmful hantaviruses can get HPS.

People get HPS when they breath in hantaviruses. This can happen when rodent urine and droppings that contain a hantavirus are stirred up into the air. People can also become infected when they touch mouse or rat urine, droppings, or nesting materials that contain the virus and then touch their eyes, nose, or mouth. They can also get HPS from a mouse or rat bite.

In the US, 10 confirmed cases of hantavirus infection in people who visited Yosemite National Park in California, US, in November 2012, were reported. Similarly, in 2017, CDC assisted health officials in investigating an outbreak of Seoul virus infection that infected 17 people in seven states.

WHAT ARE THE SYMPTOMS OF HANTAVIRUS?

If people get HPS, they will feel sick one to five weeks after they were around mice or rats that carried a hantavirus.

At first people with HPS will have:

Fever
Severe muscle aches
Fatigue

After a few days, they will have a hard time breathing. Sometimes people will have headaches, dizziness, chills, nausea, vomiting, diarrhoea, and stomach pain.

Usually, people do not have a runny nose, sore throat, or a rash.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
March 25,2020

Beijing, Mar 25: Around 5,000 people have signed up for the phase I clinical trial of recombinant novel coronavirus vaccine in Chinese city Wuhan where the virus first emerged late last year.

The recruitment for participants ended this week with nearly 5,000 volunteers signing up for the trial, state-run Beijing News reported on Wednesday.

A single-centre, open and dose-escalation phase I clinical trial for recombinant novel coronavirus vaccine (adenoviral vector) will be tested in healthy adults aged between 18 and 60 years, according to the ChiCTR (China Clinical Trial Register).

The trial, led by experts from the Academy of Military Medical Sciences, gained its approval on March 16 and the research is expected to last half a year.

Requiring at least 108 participants, the trial will be conducted in Wuhan, capital of Hubei province, the region worst-affected by the virus in the country, state-run China Daily reported.

Participants will experience 14-day quarantine restrictions after being vaccinated and their health condition will be recorded every day.

Chinese scientists are hastening the development of COVID-19 vaccines through five approaches --- inactivated vaccines, genetic engineering subunit vaccines, adenovirus vector vaccines, nucleic acid vaccines and vaccines using attenuated influenza virus as vectors.

So far, most teams are expected to complete preclinical research in April and some are moving forward faster, Wang Junzhi, an academician with the Chinese Academy of Engineering said.

Wang noted that research and development of COVID-19 vaccines in China is not slower than foreign counterparts and has been carried out in a scientific, standardised and orderly way.

China has stepped up the process to finalise vaccines to counter COVID-19 after Kaiser Permanente research facility in Seattle and Washington stole the march and began human trials.

China lifted tough restrictions on the Hubei province on Wednesday after a months-long lockdown as the country reported no new domestic cases.

But there were another 47 imported infections from overseas, the National Health Commission said. In total, 474 imported infections have been diagnosed in China -- mostly Chinese nationals returning home.

Comments

Y UDAYA CHANDAR
 - 
Monday, 13 Apr 2020

Dear Sir,

 

I am 77 but a very healthy person with remarkable immunity. I contracted Malaria fever in 1994 because of mosquito biting and I have not been sick anytime there after, not even for ordinary fever in the last 26 years.

 

I am sure you would like to conduct the trials on persons of varying criteria. I am sure you don't want to carry out the trials on perfectly healthy young individuals only. 

 

I am certain that  you want to try the vaccine on a 'common man' from 'general public.' I am ready for the trial and you can take me. I will be delighted. 

 

If you are not handling this matter kindly forward this mail to the correct agency.

 

I look forward to hearing from you.

 

Best regards.

 

If you are not moving forward, you are really moving backward.

Y Udaya Chandar

 

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
July 20,2020

Paris, Jul 20: Two coronavirus vaccine candidates have proven safe for humans and produced strong immune reactions among patients involved in separate clinical trials, doctors said on Monday.

The first trial among more than 1,000 adults in Britain found that the vaccine induced "strong antibody and T cell immune responses" against the novel coronavirus.

A separate trial in China involving more than 500 people showed most had developed widespread antibody immune response.

The studies, published in The Lancet medical journal, constitute a major step on the road towards a COVID-19 vaccine that is effective and safe for widespread use.

The authors of the studies said that they encountered few adverse side-effects from the vaccine candidates.

However, they cautioned that more research was needed, particularly among older adults, who are disproportionately at risk of dying of COVID-19.

Co-author Sarah Gilbert from the University of Oxford said the results "hold promise".

"If our vaccine is effective, it is a promising option as these types of vaccine can be manufactured at large scale."

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.